FI95045C - Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut - Google Patents

Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut Download PDF

Info

Publication number: FI95045C
Authority: FI; Finland
Prior art keywords: vector; protein; dna; cell; pres2
Prior art date: 1985-04-15

Application number

FI861559A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI861559A (fi

FI861559A0 (fi

FI95045B (fi

Inventor

John S Salstrom

Mark L Rohrbaugh

Hans A Thoma

Original Assignee

Endotronics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-15

Filing date

1986-04-14

Publication date

1995-12-11

1986-04-14 Application filed by Endotronics Inc filed Critical Endotronics Inc

1986-04-14 Publication of FI861559A0 publication Critical patent/FI861559A0/fi

1986-10-16 Publication of FI861559A publication Critical patent/FI861559A/fi

1991-09-10 Priority to FI914267A priority Critical patent/FI95726C/fi

1995-08-31 Application granted granted Critical

1995-08-31 Publication of FI95045B publication Critical patent/FI95045B/fi

1995-12-11 Publication of FI95045C publication Critical patent/FI95045C/fi

Links

108090000623 proteins and genes Proteins 0.000 title claims description 219
239000013598 vector Substances 0.000 title claims description 212
102000004169 proteins and genes Human genes 0.000 title claims description 148
238000000034 method Methods 0.000 title claims description 131
108091026890 Coding region Proteins 0.000 title claims description 89
108020004511 Recombinant DNA Proteins 0.000 title claims description 79
108091007433 antigens Proteins 0.000 title claims description 72
102000036639 antigens Human genes 0.000 title claims description 70
239000000427 antigen Substances 0.000 title claims description 67
241000700721 Hepatitis B virus Species 0.000 title claims description 64
210000004962 mammalian cell Anatomy 0.000 title claims description 35
238000004519 manufacturing process Methods 0.000 title claims description 16
239000000356 contaminant Substances 0.000 title description 2
210000004027 cell Anatomy 0.000 claims description 219
108020004414 DNA Proteins 0.000 claims description 181
239000002245 particle Substances 0.000 claims description 125
108090000765 processed proteins & peptides Proteins 0.000 claims description 89
102000004196 processed proteins & peptides Human genes 0.000 claims description 82
229920001184 polypeptide Polymers 0.000 claims description 78
239000000203 mixture Substances 0.000 claims description 52
102100031673 Corneodesmosin Human genes 0.000 claims description 47
239000002609 medium Substances 0.000 claims description 45
239000003550 marker Substances 0.000 claims description 43
101710139375 Corneodesmosin Proteins 0.000 claims description 39
108700026244 Open Reading Frames Proteins 0.000 claims description 36
239000001963 growth medium Substances 0.000 claims description 29
210000003527 eukaryotic cell Anatomy 0.000 claims description 26
238000002360 preparation method Methods 0.000 claims description 24
102000053602 DNA Human genes 0.000 claims description 22
108090000157 Metallothionein Proteins 0.000 claims description 22
241000700605 Viruses Species 0.000 claims description 20
230000003612 virological effect Effects 0.000 claims description 17
229930193140 Neomycin Natural products 0.000 claims description 16
229960004927 neomycin Drugs 0.000 claims description 16
238000011144 upstream manufacturing Methods 0.000 claims description 16
239000000758 substrate Substances 0.000 claims description 14
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 13
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 13
102000003792 Metallothionein Human genes 0.000 claims description 13
230000036961 partial effect Effects 0.000 claims description 13
238000001890 transfection Methods 0.000 claims description 13
229910001385 heavy metal Inorganic materials 0.000 claims description 11
231100000590 oncogenic Toxicity 0.000 claims description 11
230000002246 oncogenic effect Effects 0.000 claims description 11
206010059866 Drug resistance Diseases 0.000 claims description 9
229940096437 Protein S Drugs 0.000 claims description 9
230000027455 binding Effects 0.000 claims description 9
210000002950 fibroblast Anatomy 0.000 claims description 9
208000002672 hepatitis B Diseases 0.000 claims description 9
238000002955 isolation Methods 0.000 claims description 9
108060003196 globin Proteins 0.000 claims description 8
239000003270 steroid hormone Substances 0.000 claims description 8
108020005202 Viral DNA Proteins 0.000 claims description 7
238000004113 cell culture Methods 0.000 claims description 6
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
238000013518 transcription Methods 0.000 claims description 6
230000035897 transcription Effects 0.000 claims description 6
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
230000008878 coupling Effects 0.000 claims description 5
238000010168 coupling process Methods 0.000 claims description 5
238000005859 coupling reaction Methods 0.000 claims description 5
229910052725 zinc Inorganic materials 0.000 claims description 5
239000011701 zinc Substances 0.000 claims description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
229960003957 dexamethasone Drugs 0.000 claims description 4
229910052793 cadmium Inorganic materials 0.000 claims description 3
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 3
239000006166 lysate Substances 0.000 claims description 3
229910052751 metal Inorganic materials 0.000 claims 5
239000002184 metal Substances 0.000 claims 5
150000001875 compounds Chemical class 0.000 claims 4
229910021645 metal ion Inorganic materials 0.000 claims 2
108700020796 Oncogene Proteins 0.000 claims 1
108010076830 Thionins Proteins 0.000 claims 1
239000000411 inducer Substances 0.000 claims 1
239000004922 lacquer Substances 0.000 claims 1
ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
239000013612 plasmid Substances 0.000 description 171
235000018102 proteins Nutrition 0.000 description 126
239000012634 fragment Substances 0.000 description 90
239000000243 solution Substances 0.000 description 77
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
230000001580 bacterial effect Effects 0.000 description 37
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
108091008146 restriction endonucleases Proteins 0.000 description 34
239000007983 Tris buffer Substances 0.000 description 30
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 30
241000699666 Mus <mouse, genus> Species 0.000 description 27
101150115433 SLC26A5 gene Proteins 0.000 description 27
239000000463 material Substances 0.000 description 26
239000000499 gel Substances 0.000 description 25
229960005486 vaccine Drugs 0.000 description 25
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
150000001413 amino acids Chemical class 0.000 description 24
210000002966 serum Anatomy 0.000 description 24
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
235000001014 amino acid Nutrition 0.000 description 20
239000011780 sodium chloride Substances 0.000 description 20
238000012360 testing method Methods 0.000 description 19
241000894006 Bacteria Species 0.000 description 18
239000000047 product Substances 0.000 description 18
238000003127 radioimmunoassay Methods 0.000 description 18
239000000523 sample Substances 0.000 description 18
239000000872 buffer Substances 0.000 description 17
238000002474 experimental method Methods 0.000 description 17
239000011543 agarose gel Substances 0.000 description 16
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 16
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
239000002953 phosphate buffered saline Substances 0.000 description 16
230000010076 replication Effects 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
241001465754 Metazoa Species 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 15
230000029087 digestion Effects 0.000 description 15
229940088598 enzyme Drugs 0.000 description 15
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
241000699670 Mus sp. Species 0.000 description 14
210000000349 chromosome Anatomy 0.000 description 14
108020004705 Codon Proteins 0.000 description 13
101100082633 Drosophila melanogaster nub gene Proteins 0.000 description 13
238000007796 conventional method Methods 0.000 description 13
206010028980 Neoplasm Diseases 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 12
238000009396 hybridization Methods 0.000 description 12
229920001817 Agar Polymers 0.000 description 11
108091003079 Bovine Serum Albumin Proteins 0.000 description 11
241000701822 Bovine papillomavirus Species 0.000 description 11
108010000521 Human Growth Hormone Proteins 0.000 description 11
239000008272 agar Substances 0.000 description 11
238000005119 centrifugation Methods 0.000 description 11
230000006870 function Effects 0.000 description 11
230000012010 growth Effects 0.000 description 11
238000011534 incubation Methods 0.000 description 11
230000008488 polyadenylation Effects 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
239000000020 Nitrocellulose Substances 0.000 description 10
101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 10
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
229960000723 ampicillin Drugs 0.000 description 10
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
239000003814 drug Substances 0.000 description 10
239000012091 fetal bovine serum Substances 0.000 description 10
229920001220 nitrocellulos Polymers 0.000 description 10
102000012410 DNA Ligases Human genes 0.000 description 9
108010061982 DNA Ligases Proteins 0.000 description 9
101001134680 Drosophila melanogaster POU domain protein 2, isoform A Proteins 0.000 description 9
101001134679 Drosophila melanogaster POU domain protein 2, isoform B Proteins 0.000 description 9
101001134678 Drosophila virilis POU domain protein 2 Proteins 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
239000002202 Polyethylene glycol Substances 0.000 description 9
238000010276 construction Methods 0.000 description 9
229940079593 drug Drugs 0.000 description 9
150000002500 ions Chemical class 0.000 description 9
229920001223 polyethylene glycol Polymers 0.000 description 9
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
239000000725 suspension Substances 0.000 description 9
230000009466 transformation Effects 0.000 description 9
102000002265 Human Growth Hormone Human genes 0.000 description 8
239000000854 Human Growth Hormone Substances 0.000 description 8
108010031318 Vitronectin Proteins 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 8
238000010367 cloning Methods 0.000 description 8
238000000605 extraction Methods 0.000 description 8
239000002054 inoculum Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
239000011734 sodium Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000012546 transfer Methods 0.000 description 8
102000004594 DNA Polymerase I Human genes 0.000 description 7
108010017826 DNA Polymerase I Proteins 0.000 description 7
229960000583 acetic acid Drugs 0.000 description 7
238000003556 assay Methods 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
230000008569 process Effects 0.000 description 7
239000011535 reaction buffer Substances 0.000 description 7
210000003501 vero cell Anatomy 0.000 description 7
241000699802 Cricetulus griseus Species 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
241000233866 Fungi Species 0.000 description 6
241000204031 Mycoplasma Species 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
229940037003 alum Drugs 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000011324 bead Substances 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
238000011109 contamination Methods 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
108010045897 polyalbumin Proteins 0.000 description 6
239000002243 precursor Substances 0.000 description 6
230000007017 scission Effects 0.000 description 6
210000005253 yeast cell Anatomy 0.000 description 6
208000002109 Argyria Diseases 0.000 description 5
241000972773 Aulopiformes Species 0.000 description 5
108020003215 DNA Probes Proteins 0.000 description 5
239000003298 DNA probe Substances 0.000 description 5
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
101100351324 Homo sapiens PDPN gene Proteins 0.000 description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
239000006142 Luria-Bertani Agar Substances 0.000 description 5
102100037265 Podoplanin Human genes 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
101150010882 S gene Proteins 0.000 description 5
235000014121 butter Nutrition 0.000 description 5
239000013611 chromosomal DNA Substances 0.000 description 5
238000012761 co-transfection Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
230000036512 infertility Effects 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
235000019515 salmon Nutrition 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
-1 GP33 Proteins 0.000 description 4
108091006905 Human Serum Albumin Proteins 0.000 description 4
102000008100 Human Serum Albumin Human genes 0.000 description 4
102100034349 Integrase Human genes 0.000 description 4
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 4
241000473945 Theria <moth genus> Species 0.000 description 4
108010022394 Threonine synthase Proteins 0.000 description 4
241001105470 Valenzuela Species 0.000 description 4
244000309466 calf Species 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
102000004419 dihydrofolate reductase Human genes 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
238000002523 gelfiltration Methods 0.000 description 4
239000012510 hollow fiber Substances 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
239000008188 pellet Substances 0.000 description 4
238000011084 recovery Methods 0.000 description 4
239000001509 sodium citrate Substances 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
238000013112 stability test Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000003860 storage Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
230000005030 transcription termination Effects 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
101710132601 Capsid protein Proteins 0.000 description 3
102100031780 Endonuclease Human genes 0.000 description 3
108010042407 Endonucleases Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
101710188315 Protein X Proteins 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
108020005038 Terminator Codon Proteins 0.000 description 3
239000003708 ampul Substances 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
108091092356 cellular DNA Proteins 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
238000009826 distribution Methods 0.000 description 3
210000003754 fetus Anatomy 0.000 description 3
238000011049 filling Methods 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
239000012145 high-salt buffer Substances 0.000 description 3
239000007943 implant Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
210000005229 liver cell Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 3
238000007747 plating Methods 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
239000006152 selective media Substances 0.000 description 3
241000894007 species Species 0.000 description 3
230000003068 static effect Effects 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
230000035899 viability Effects 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102100026189 Beta-galactosidase Human genes 0.000 description 2
0 C=*C1C=CCC1 Chemical compound C=*C1C=CCC1 0.000 description 2
102100035893 CD151 antigen Human genes 0.000 description 2
101710118846 CD151 antigen Proteins 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
101710173438 Late L2 mu core protein Proteins 0.000 description 2
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
101710094503 Metallothionein-1 Proteins 0.000 description 2
101710082270 Metallothionein-like protein 1 Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
241001045988 Neogene Species 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
108010059712 Pronase Proteins 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
241000711975 Vesicular stomatitis virus Species 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000005903 acid hydrolysis reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000001641 gel filtration chromatography Methods 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000002372 labelling Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
101150091879 neo gene Proteins 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
239000013014 purified material Substances 0.000 description 2
238000003908 quality control method Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
101710134784 Agnoprotein Proteins 0.000 description 1
229910002703 Al K Inorganic materials 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
244000153158 Ammi visnaga Species 0.000 description 1
235000010585 Ammi visnaga Nutrition 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
108010027805 Azocoll Proteins 0.000 description 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
241000293679 Boraria media Species 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
241000388186 Deltapapillomavirus 4 Species 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
241000709701 Human poliovirus 1 Species 0.000 description 1
241000709704 Human poliovirus 2 Species 0.000 description 1
241000709727 Human poliovirus 3 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
241000282579 Pan Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000015623 Polynucleotide Adenylyltransferase Human genes 0.000 description 1
108010024055 Polynucleotide adenylyltransferase Proteins 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000006159 Sabouraud's agar Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
241001148470 aerobic bacillus Species 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000009713 electroplating Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000012757 fluorescence staining Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000001894 hemadsorption Effects 0.000 description 1
108010050151 hepatitis B hyperimmune globulin Proteins 0.000 description 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
229940124736 hepatitis-B vaccine Drugs 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000001738 isopycnic centrifugation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
230000017156 mRNA modification Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
229940031348 multivalent vaccine Drugs 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
231100000707 mutagenic chemical Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
QSHGUCSTWRSQAF-FJSLEGQWSA-N s-peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C1=CC=C(OS(O)(=O)=O)C=C1 QSHGUCSTWRSQAF-FJSLEGQWSA-N 0.000 description 1
239000012449 sabouraud dextrose agar Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940126577 synthetic vaccine Drugs 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000006150 trypticase soy agar Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000005727 virus proliferation Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Pathology (AREA)
Endocrinology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Virology (AREA)
Toxicology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

FI861559A 1985-04-15 1986-04-14 Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut FI95045C (fi)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
FI914267A FI95726C (fi)	1985-04-15	1991-09-10	Diagnostiset menetelmät ja määrityssarjat, joissa käytetään yhdistelmä-DNA-tekniikalla muodostettua hepatitis B -viruksen pinta-antigeenia

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
EP85104521		1985-04-15
EP85104521		1985-04-15
US85056786A	1986-04-11	1986-04-11
US85056786		1986-04-11

Publications (4)

Publication Number	Publication Date
FI861559A0 FI861559A0 (fi)	1986-04-14
FI861559A FI861559A (fi)	1986-10-16
FI95045B FI95045B (fi)	1995-08-31
FI95045C true FI95045C (fi)	1995-12-11

Family

ID=26096680

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI861559A FI95045C (fi)	1985-04-15	1986-04-14	Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut

Country Status (9)

Country	Link
KR (1)	KR960004264B1 (ko)
AU (1)	AU606574B2 (ko)
DK (1)	DK171386A (ko)
FI (1)	FI95045C (ko)
HU (1)	HUT40699A (ko)
NO (1)	NO861450L (ko)
NZ (1)	NZ215820A (ko)
OA (1)	OA08238A (ko)
PT (1)	PT82392B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR970007153B1 (ko) *	1987-06-22	1997-05-03	메데바 홀딩스 비브이	B형 간염 표면 항원 백신

1986
- 1986-04-14 FI FI861559A patent/FI95045C/fi not_active IP Right Cessation
- 1986-04-14 NO NO861450A patent/NO861450L/no unknown
- 1986-04-14 NZ NZ215820A patent/NZ215820A/xx unknown
- 1986-04-15 OA OA58835A patent/OA08238A/xx unknown
- 1986-04-15 PT PT82392A patent/PT82392B/pt not_active IP Right Cessation
- 1986-04-15 HU HU861577A patent/HUT40699A/hu unknown
- 1986-04-15 KR KR1019860002859A patent/KR960004264B1/ko not_active IP Right Cessation
- 1986-04-15 DK DK171386A patent/DK171386A/da not_active Application Discontinuation
- 1986-04-15 AU AU56114/86A patent/AU606574B2/en not_active Ceased

Also Published As

Publication number	Publication date
FI861559A (fi)	1986-10-16
NO861450L (no)	1986-10-16
KR960004264B1 (ko)	1996-03-30
PT82392A (en)	1986-05-01
HUT40699A (en)	1987-01-28
NZ215820A (en)	1989-01-06
DK171386D0 (da)	1986-04-15
DK171386A (da)	1986-10-16
PT82392B (pt)	1988-03-03
OA08238A (en)	1987-10-30
KR860008284A (ko)	1986-11-14
FI861559A0 (fi)	1986-04-14
FI95045B (fi)	1995-08-31
AU606574B2 (en)	1991-02-14
AU5611486A (en)	1986-10-23

Legal Events

Date	Code	Title	Description
1995-08-02	BB	Publication of examined application
2004-08-31	MM	Patent lapsed	Owner name: ENDOTRONICS, INC.

Publication	Publication Date	Title
EP0198474B1 (en)	1996-06-26	Hepatitis B surface antigen formed by recombinant DNA techniques, vaccines, diagnostics, cell lines and methods of forming same
Tiollais et al.	1981	Biology of hepatitis B virus
FI86437C (fi)	1992-08-25	Foerfarande foer framstaellning av polypeptider med de antigena egenskaperna hos ett hepatitis b- virusantigen.
Michel et al.	1984	Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin.
Klingmüller et al.	1993	Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor
US6117653A (en)	2000-09-12	Hepatitis B surface antigen vaccine
JP2003093081A (ja)	2003-04-02	Ｃ型肝炎ウイルスアシアロ糖タンパク質
AU594642B2 (en)	1990-03-15	A sv40 expression vector containing hbxag as an expression marker
US5324513A (en)	1994-06-28	Composition useful for the fabrication of vaccines
Schlicht et al.	1991	The quaternary structure, antigenicity, and aggregational behavior of the secretory core protein of human hepatitis B virus are determined by its signal sequence
EP0182442B1 (en)	1990-07-11	Recombinant dna molecules and their method of production
NZ204952A (en)	1986-05-09	Hepatitis b virus vaccine
Delpeyroux et al.	1990	Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles
Gerlich	1993	Structure and molecular virology
FI95045C (fi)	1995-12-11	Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut
Seifer et al.	1990	Expression pattern of the hepatitis B virus genome in transfected mouse fibroblasts
KR970007153B1 (ko)	1997-05-03	B형 간염 표면 항원 백신
EP0301083A1 (en)	1989-02-01	Retroviral expression vectors and methods for producing hbv antigens
Borel et al.	1998	Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle
US5077213A (en)	1991-12-31	Recombinant vaccinia virus
SK118293A3 (en)	1994-03-09	Multiple hepatitis b virus surface proteins which form particles
FI95726B (fi)	1995-11-30	Diagnostiset menetelmät ja määrityssarjat, joissa käytetään yhdistelmä-DNA-tekniikalla muodostettua hepatitis B -viruksen pinta-antigeenia
US6268122B1 (en)	2001-07-31	Recombinant DNA molecules and their method of production
KOIKE et al.	1987	Production of hepatitis B virus surface antigen particles by the human hepatoma cell line huGK-14 in a serum-free medium
CA1340934C (en)	2000-03-28	Hepatitis b surface antigen formed by recombinant dna techniques, vaccines, diagnostics, cell lines and method of forming same